Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

OBJECTIVE: Huntington's disease (HD) is an autosomal dominant disorder characterised by motor, cognitive and psychiatric disturbances. Several studies have demonstrated that hypothalamic dysfunction is part of the phenotypic spectrum. The aim of the study was to evaluate the growth hormone (GH) response to arginine infusion in a cohort of HD patients, to search for an in vivo biomarker of hypothalamic dysfunction. METHODS: The authors investigated 17 HD patients and 17 age-, sex- and BMI-matched healthy controls. Clinical assessment of patients was performed using the Unified Huntington's Disease Rating Scale motor section and total function capacity. Metabolic and endocrine investigations included total, LDL and HDL cholesterol, basal insulin, GH, insulin-like growth factor 1 (IGF-1), SD Score IGF-1 (SDS IGF-1) and the GH response to arginine stimulation. RESULTS: HD patients showed lower plasma IGF-1 and SDS IGF-1 levels and a higher baseline GH in comparison with control subjects. The arginine test induced a normal GH peak in nine patients (53%; Arg+), whereas the response was absent in the remaining eight (47%; Arg-). Arg+ and Arg- also showed two distinct endocrine/metabolic profiles with differences in insulin and lipid metabolism. CONCLUSION: It remains to be clarified if these two subgroups of patients, according to the GH response to arginine, correspond to different disease stages or to different patterns of neurodegeneration.

Original publication

DOI

10.1136/jnnp.2010.208553

Type

Journal article

Journal

J Neurol Neurosurg Psychiatry

Publication Date

05/2011

Volume

82

Pages

543 - 547

Keywords

Adult, Aged, Arginine, Case-Control Studies, Cholesterol, HDL, Cholesterol, LDL, Female, Human Growth Hormone, Humans, Huntington Disease, Insulin, Insulin-Like Growth Factor I, Male, Middle Aged, Severity of Illness Index